Does treatment of childhood congenital adrenal hyperplasia with prednisone adversely affect final height?

2007 ◽  
Vol 3 (9) ◽  
pp. 626-627
Author(s):  
Ryan Miller ◽  
Sally Radovick
Keyword(s):  
Congenital Adrenal Hyperplasia ◽  
Final Height ◽  
Adrenal Hyperplasia

Near-final height in 82 Chinese patients with congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency: a single-center study from China

2016 ◽  
Vol 29 (7) ◽  
Author(s):  
Lin Juan ◽  
Ma Huamei ◽  
Su Zhe ◽  
Li Yanhong ◽  
Chen Hongshan ◽  
...  
Keyword(s):  
Treatment Group ◽  
Congenital Adrenal Hyperplasia ◽  
Early Treatment ◽  
Final Height ◽  
Adrenal Hyperplasia ◽  
Target Height ◽  
Hydroxylase Deficiency ◽  
Cox Regression Analysis ◽  
Late Treatment ◽  
21 Hydroxylase Deficiency

AbstractThe objective of this study was to identify variables that might interfere with reaching the near final height (NFH) in Congenital adrenal hyperplasia (CAH) due to classic 21-hydroxylase deficiency (21-OHD).A cross-sectional study of 82 (24 males and 58 females) classic (23 salt-wasting form [SW] and 59 simple-virilizing form [SV]) CAH 21-OHD patients seen in our institution between 1989 and 2015 with 10.6 (0.5~25.5) years of follow-up who reached their NFH was conducted. The variables related to NFH were explored.NFH (153.35±8.31) cm, (–1.9±1.1) SD was significantly lower than the normal population (p<0.001). The treated patients reached a significantly higher NFH (–1.7±1.1) SD than those untreated (–2.6±1.0) SD (p<0.05). Both of early treatment and late treatment group were taller than untreated group (p<0.001, p=0.013, respectively), and early treatment group had a taller height trend than late treatment group (p=0.089). A better height outcome was observed in patients with advantage in target height, good compliance, and low hydrocortisone dose by multivariate Cox regression analysis in 62 treatment patients. NFH and hydrocortisone dose was negatively correlated (r=–0.23, p=0.078) in treated group. Patients complicated by central precocious puberty (CPP) received gonadotropin-releasing hormone analogue (GnRHa) plus letrozole had increased NFH with height SD for bone age and Ht SD improved after treatment compare to no intervention group (p=0.001, p=0.035).Patients with classic 21-OHD have blunted final height, as compared with their target height and the population norm, not-treated even worse. Careful treatment adjustments have a favorable influence on growth. Alternative treatments, such as the use of puberty inhibitors GnRHa in addition to anti-estrogen therapy letrozole can somewhat improve NFH in children with 21-OHD complicated by CPP.

Growth Patterns and Final Height in Congenital Adrenal Hyperplasia due to Classical 21-Hydroxylase Deficiency

2001 ◽  
Vol 55 (4) ◽  
pp. 161-171 ◽  
Author(s):  
Gábor Hargitai ◽  
János Sólyom ◽  
Tadej Battelino ◽  
Jan Lebl ◽  
Zuzanna Pribilincová ◽  
...  
Keyword(s):  
Congenital Adrenal Hyperplasia ◽  
Final Height ◽  
Growth Patterns ◽  
Adrenal Hyperplasia ◽  
Hydroxylase Deficiency ◽  
21 Hydroxylase Deficiency

scholarly journals Final height of a group of patients with congenital adrenal hyperplasia

2013 ◽  
Author(s):  
Marta Ferreira ◽  
Sonia Santos ◽  
Ester Pereira ◽  
Beatriz Vale ◽  
Rita Cardoso ◽  
...  
Keyword(s):  
Congenital Adrenal Hyperplasia ◽  
Final Height ◽  
Adrenal Hyperplasia

The effect of treatment of final height in classical congenital adrenal hyperplasia (CAH)

1986 ◽  
Vol 113 (4_Suppl) ◽  
pp. S305-S314 ◽  
Author(s):  
Joan DiMartino-Nardi ◽  
Elizabeth Stoner ◽  
Alyce O'Connell ◽  
Maria I. New
Keyword(s):  
Congenital Adrenal Hyperplasia ◽  
Final Height ◽  
Adrenal Hyperplasia ◽  
Effect Of Treatment

scholarly journals Near-final height in patients with congenital adrenal hyperplasia treated with combined therapy using GH and GnRHa

2011 ◽  
Vol 55 (8) ◽  
pp. 661-664 ◽  
Author(s):  
Carlos Alberto Longui ◽  
Cristiane Kochi ◽  
Luís Eduardo Procópio Calliari ◽  
Maria Barcellos Rosa Modkovski ◽  
Marisa Soares ◽  
...  
Keyword(s):  
Congenital Adrenal Hyperplasia ◽  
Precocious Puberty ◽  
Combined Therapy ◽  
Final Height ◽  
Standard Deviation Score ◽  
Central Precocious Puberty ◽  
Bone Age ◽  
Hormonal Control ◽  
Adrenal Hyperplasia ◽  
Gh Treatment

INTRODUCTION: Intrinsic limitations of glucocorticoid therapy in patients with congenital adrenal hyperplasia (CAH) determine frequent loss in final height. The association of secondary central precocious puberty and early epiphyseal fusion is also frequent. In these conditions, GnRHa treatment alone or in combination with GH has been indicated. OBJECTIVES: This is a retrospective study, describing the estatural findings of CAH patients with significant decrease in height prediction, who were submitted to combined GH plus GnRHa therapy up to near-final height. SUBJECTS AND METHODS: We studied 13 patients, eight females and five males, eight with the classical and five with the nonclassical form of the disorder. Treatment with hydrocortisone (10-20 mg/m²/day) or prednisolone (3-6 mg/kg/day) was associated with GnRHa (3.75 mg/months) for 4.0 (1.5) years, and GH (0.05 mg/kg/day) for 3.6 (1.4) years. RESULTS: Stature standard deviation score for bone age improved significantly after GH treatment, becoming similar to target height at the end of the second year of GH treatment. CONCLUSION: We conclude that combined GH plus GnRHa therapy can be useful in a subset of CAH patients with significant reduction of predicted final height associated with poor hormonal control and central precocious puberty.

Sign in / Sign up

Export Citation Format

Share Document